NVAX
HOLD / NEUTRALMeanRevComposite
57.50
Technical
43.40
Fundamental
62.20
Rank
—
Price
8.79
Hurst
0.11
As of
Aug 20, 2026
Daily
Novavax, Inc.
HealthcareBiotechnologyNovavax is a biotechnology firm that develops and markets vaccines against serious infections globally. The company offers Nuvaxovid for COVID-19 prevention and R21, a malaria vaccine using Matrix-M adjuvant technology. Through partnerships with major pharmaceutical firms including Sanofi, Pfizer, and Takeda, Novavax manufactures and distributes its COVID-19 vaccine across multiple regions.
Market cap
$1.6B
P/E (trailing)
—
P/E (forward)
-16.29
PEG ratio
1.32
Dividend yield
—
Beta
2.45
52w range
6.20 – 11.97
Return on equity
—
Profit margin
-59.87%
Revenue growth
-76.30%
Earnings growth
—
Price history
1Y: 10.00 (+17.2%) · range 6.22–11.19
Cycle position
71/ 100 cycle scoreAPPROACHING EXIT
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 11 · NOT READY · exit proximity 0
Conviction
23/ 100 · maturity 100%
VScore.408
Buildup.2038
EMA entry setup.2511
Fundamentals.1562
Volume profile
POC
9.34
Price vs POC
+7.1%
Overhead supply
16%
Runway
open sky
Value area 7.77–9.74 · 16% of 120d volume overhead · clean runway
Contributing sources
| Source | Score | Last seen |
|---|---|---|
| trader-sentiment | 0.095 | Sep 3, 2026 |
| earnings-surprise | 0.025 | Sep 4, 2026 |
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | +11.88% | +22.80% | 15/20d |
| 40d | +11.88% | +22.80% | 15/40d |